BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 34482117)

  • 1. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
    Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
    Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.
    Zhang P; Zhou C; Ren X; Jing Q; Gao Y; Yang C; Shen Y; Zhou Y; Hu W; Jin F; Xu H; Yu L; Liu Y; Tong X; Li Y; Wang Y; Du J
    Redox Biol; 2024 Feb; 69():103007. PubMed ID: 38150993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma.
    Zhao Y; Zhu S
    Biochem Genet; 2024 Feb; 62(1):144-155. PubMed ID: 37286868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.
    Ni X; Ye C; Yu X; Zhang Y; Hou Y; Zheng Q; Chen Z; Wang L; Weng X; Yang C; Liu X
    Eur J Pharmacol; 2023 Dec; 960():176110. PubMed ID: 37838104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
    Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Elkateb AS; Nofal S; Ali SA; Atya HB
    Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
    Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
    J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway.
    Li Y; Xu B; Ren X; Wang L; Xu Y; Zhao Y; Yang C; Yuan C; Li H; Tong X; Wang Y; Du J
    Cell Mol Biol Lett; 2022 Sep; 27(1):81. PubMed ID: 36180832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
    Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
    Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
    Chu M; An X; Fu C; Yu H; Zhang D; Li Q; Man X; Dai X; Li Z
    Front Biosci (Landmark Ed); 2023 Aug; 28(8):186. PubMed ID: 37664913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram.
    Zhang G; Wang Y; Fuchs BC; Guo W; Drum DL; Erstad DJ; Shi B; DeLeo AB; Zheng H; Cai L; Zhang L; Tanabe KK; Wang X
    Front Oncol; 2022; 12():913736. PubMed ID: 35912209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
    Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
    Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
    Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
    Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
    Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
    Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.
    Zhang D; Man D; Lu J; Jiang Y; Ding B; Su R; Tong R; Chen J; Yang B; Zheng S; Chen D; Wu J
    Adv Sci (Weinh); 2023 May; 10(15):e2206669. PubMed ID: 36994647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
    Chiba T; Suzuki E; Yuki K; Zen Y; Oshima M; Miyagi S; Saraya A; Koide S; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Nakatsura T; Hayashi T; Yamashita T; Kaneko S; Miyazaki M; Iwama A; Yokosuka O
    PLoS One; 2014; 9(1):e84807. PubMed ID: 24454751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.